Simultaneous integrated boost and protection proton beam therapy approach for hepatocellular carcinoma
Kanokphorn Thonglert, Matthew D. Greer, Stephanie K. Schaub and 9 more
Clinical and Translational Radiation Oncology · 2025
doi:10.1016/j.ctro.2025.101008 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Purpose: Although simultaneous integrated boost and protection with proton beam therapy (SIB-PBT) facilitates tumor dose escalation while maintaining organ-at-risk (OAR) dose constraints, clinical outcomes are limited. This study assessed the safety and efficacy of using the SIB-PBT technique in hepatocellular carcinoma (HCC) patients. Methods: We reviewed 47 patients with HCC who underwent SIB-PBT between 2014–2021. The radiation dose ranged from 36-67.5 Gy(RBE) in 15 fractions. SIB-PBT was used for the following reasons: minimize high-dose exposure to organs-at-risk (OARs) (n = 22, 47 %), treat targets with different dose levels (n = 6, 13 %), or both (n = 19, 40 %). Survival, local control, and toxicities were assessed using Kaplan-Meier, Fine-Gray cumulative incidence, and descriptive statistics, respectively. Results: Forty-one patients (87 %) had tumors located ≤2 cm from luminal gastrointestinal (GI) OARs. The median tumor diameter was 9.2 cm (range, 2.0–21.5 cm). The median EQD2 D50%, D95% and D99% of gross tumor volume were 79.8 (range, 51.1–85.9), 66.7 (range, 36.9–84.6) and 50.2 (range, 34.1–83.6) Gy(RBE)10, respectively. Most patients (91 %) received a D0.5 cc of <45 Gy(RBE) to luminal GI OARs. At a median follow-up of 22 months (range, 0.8–77.0 months), the 2-year cumulative incidence of local failure was 12 %. The 2-year progression-free survival and overall survival rates were 12 % (95 % CI 4.7–23.4 %), and 49 % (95 % CI, 33.2–63.2 %), respectively. One patient experienced grade 3 acute nausea/vomiting. No GI bleeding/ulcers or grade 4 + toxicity were observed. CP + 2 occurred in 5 patients. Conclusion: SIB-PBT enables OAR protection along with heterogeneous tumor dose escalation and is a safe and effective treatment for HCC tumors.
Abstract licence: CC BY-NC-ND
References26
26 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.